5-year follow-up of an RCT in 120 patients with recurrent Ta non-muscle-invasive bladder cancer: mitomycin C chemoresection vs TURBT meant fewer TURBTs (64% vs 89%). Recurrence-free survival (14% vs 28%) did not differ significantly (HR 1.32, 95% CI 0.86–2.01).
RCTn = 120
Klingenberg et al. DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer